Currently, 3 clinically validated biomarkers are FDA-approved to predict patient response to ICI treatment: PD-L1 expression2–6, microsatellite instability (MSI) / mismatch repair deficiency (dMMR)5,7, and tumor mutational burden8. This evidence concerns the gene CD274 and neoplasm.